CIR-0602K insulin sensitizer for people using AID
What this study tests
University of Virginia phase 2 trial testing Cirius Therapeutics CIR-0602K to improve time in range and lower insulin dose in adults with T1D using closed-loop automated insulin delivery.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-02-25.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults 18-45 with T1D for at least 1 year, using Dexcom G7-compatible closed-loop AID; HbA1c below 10% plus BMI/insulin-dose and other protocol criteria apply. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted yet.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Glucose time in range (70–180 mg/dL) over 12 weeks
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT07186660: CIR-0602K insulin sensitizer for people using AID · Trial registry